Liminatus Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
IBA101 Phase 1 Trial Initiation QuarterlyTarget: Initiate Phase 1 dose-escalation clinical trial in early 2027
IBC101 Phase 1/2a Clinical Progress QuarterlyTarget: Advance Phase 1/2a clinical study in relapsed or refractory DLBCL at Seoul St. Mary's Hospital
Cash and Cash Equivalents Quarterly1.9MTarget: Secure additional non-dilutive or equity financing to extend cash runway
Watch Items
- Nasdaq Delisting Appeal OutcomeTrigger: Nasdaq Hearings Panel decision on continued listing complianceAction: Present a viable compliance plan to regain the $50M market value of listed securities and $15M market value of publicly held shares
- InnocsAI Merger Stockholder ApprovalTrigger: Stockholder vote on the issuance of 1.6 billion common sharesAction: Prepare and file SEC registration statement containing the proxy statement/prospectus
- IBA101 Preclinical Safety and IND FilingTrigger: Filing of Investigational New Drug (IND) application for IBA101Action: Complete regulatory preparations in the U.S. and South Korea to support early 2027 clinical entry
Research as of 20 Jun 2026